Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 10/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15782836 | 0.86 | L3MBTL1 (0.36) | NR1H2NR1H3L3MBTL1MAPTRAB9A | |
| SCHEMBL15782827 | 0.84 | MAPT (0.33) | NR1H2L3MBTL1MAPTRAB9ANPSR1 | |
| SCHEMBL10161423 | 0.80 | MAPT (0.36) | MAPTRAB9ANPSR1ELANE | |
| SCHEMBL14220489 | 0.78 | MAPT (0.34) | NR1H2L3MBTL1MAPTELANE | |
| SCHEMBL15782825 | 0.78 | MAPT (0.36) | NR1H2NR1H3L3MBTL1MAPTELANE | |
| SCHEMBL15782845 | 0.78 | KCNA3 (0.34) | L3MBTL1MAPTRAB9AELANE | |
| SCHEMBL12948220 | 0.78 | ALDH1A1 (0.43) | NR1H2L3MBTL1MAPTRAB9ANPSR1 | |
| SCHEMBL15782826 | 0.76 | BRD4 (0.33) | MAPTELANE | |
| SCHEMBL15782921 | 0.76 | L3MBTL1 (0.39) | NR1H2L3MBTL1MAPTTNK2 | |
| SCHEMBL10161473 | 0.75 | ELANE (0.31) | ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9365493-B2 | Synthesis of tetracyclines and analogues thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-06-14 | — | — | US | disclosed |
| US-20140163238-A1 | SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163238-A1 | SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF | TET1, TET3, MYC | ACLY 2210/4885NR1H2 2886/4885NR1H3 3014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.